TERT promoter mutations and long-term survival in patients with thyroid cancer

  1. Jae Hoon Chung1
  1. 1Division of Endocrinology and Metabolism, Department of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
  2. 2Green Cross Genome, Yongin, Korea
  3. 3Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
  4. 4Center for Clinical Medicine, Samsung Biomedical Research Institute, Samsung Medical Center, Seoul, Korea
  5. 5Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
  6. 6Biostatistics and Clinical Epidemiology Center, Research Institute for Future Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
  7. 7Samsung Genome Institute, Samsung Medical Center, Seoul, Korea
  8. 8Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Suwon, Korea
  9. 9Division of Breast and Endocrine Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
  1. Correspondence should be addressed to J H Chung; Email: thyroid{at}skku.edu
  1. Figure 1

    Kaplan–Meier curves of thyroid cancer-specific survival by TERT mutational status. Results from the analysis of patients with (A) differentiated thyroid cancer and (B) papillary thyroid cancer. A full colour version of this figure is available at http://dx.doi.org/10.1530/ERC-16-0219.

  2. Figure 2

    Kaplan–Meier curves of thyroid cancer-specific survival by four genotypes according to the TERT and BRAF mutational status. Results from the analysis of patients with papillary thyroid cancer. A full colour version of this figure is available at http://dx.doi.org/10.1530/ERC-16-0219.

| Table of Contents